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The relationship between the two biologically ac-
tive thyroid hormones, free thyroxine (fT4) and free 
triiodothyronine (fT3), and thyroid stimulating hor-
mone (TSH), the pituitary hormone that controls 
them, is tightly preserved in many diverse physio-
logical and pathological conditions. Blood con-
centrations of fT4 and fT3 are maintained within a 
narrow range, which remains constant throughout 
life with little intra-individual variability (1,2). This 
constancy probably reflects an individual’s pitui-
tary “set point” (3). This close relationship is impor-
tant because of the wide array of physiological ac-
tivities that thyroid hormones influence. Both 
auto immune and non-autoimmune intrinsic thy-
roid diseases (e.g. Graves’ disease (GD), Hashimo-
to’s thyroiditis (HT) or nodular thyroid disease) 
have the potential to disturb this relationship. The 
resulting thyroid hormone abnormalities and the 
new “steady state” are predictable and are easy to 
understand because the changes are concordant. 
For example, in GD there is stimulation of the TSH 
receptor by the thyrotropin receptor antibody 
(TRAb), resulting in increased blood concentra-
tions of fT4 and fT3 (4). The finely tuned negative 
feedback mechanism called the hypothalamic-pi-
tuitary-thyroid axis (HPT) causes inhibition of the 
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malities is also low (about 7%). As many studies indicate, thyroid tests are expensive and consume large amounts of the hospital budget and resour-
ces of hospital laboratories. Other studies have shown that when abnormalities are detected, clinicians do not intervene or follow up these subjects. 
Therefore the clinical utility of thyroid testing in acutely ill patients is debatable. Interventions to change requestor behaviour with regard to thyroid 
testing in acutely ill subjects and the success of some audit and educational interventions are worthy of note. 
Thyroid testing in acutely ill patients is often an expensive distraction and is of limited clinical value. Targeted thyroid testing should be offered in 
this group only to those with: (a) symptoms or signs of thyroid disease e.g. goiter or orbitopathy; (b) risk factors for thyroid disease, previous or fa-
mily history of thyroid disease; (c) taking drugs which potentially affect thyroid function e.g. thyroxine replacement therapy, amiodarone, lithium, 
mechanistic target of rapamycin (mTOR) inhibitors, interferon, alemtuzumab etc; (d) unexplained tachydysrhythmias.
Key words: thyroid tests; acute illness; guidelines
Received: October 16, 2016 Accepted: February 15, 2017 
Thyroid testing in acutely ill patients may be an expensive distraction 
Lakdasa D. Premawardhana*1,2
1Section of Endocrinology, YYF Hospital, Caerphilly, UK
2Centre for Endocrine and Diabetes Sciences, University Hospital of Wales, Cardiff, UK
*Corresponding author: premawardhanald@cardiff.ac.uk
https://doi.org/10.11613/BM.2017.033 Biochemia Medica 2017;27(2):300–7 
  301
Premawardhana LD. Thyroid tests and acute illness
thyrotrophic hormones, suppressing TSH concen-
trations often into the undetectable range (5). The 
opposite happens in HT where decreased blood 
concentrations of fT4 and fT3, cause thyrotrophs to 
increase TSH secretion (6). Clinicians can therefore 
derive information about current thyroid homeo-
stasis by measuring fT4 and fT3, the biologically ac-
tive forms of these hormones currently preferred 
by most laboratories, and TSH in the blood.
Such thyroid hormone testing is common these 
days (7). The availability of technically simple, quick 
and relatively cheap automated analysers has in-
creased the demand on laboratories all over the 
world. The United Kingdom (UK) has seen an expo-
nential rise in the number of thyroid tests every year 
- 10 million thyroid tests which included fT4, fT3 
and TSH, costing an estimated 30 million sterling 
pounds a year (8,9). The biochemistry laboratory in 
our hospital in Cardiff which has approximately 
1000 beds and serves a population of about 
500,000 did 129,953 combined fT4 and TSH tests, 
15,949 TSH tests alone, and about 4600 fT3 tests in 
the year 2013/14. The cost for reagents alone was 
approximately £56,000 (about 2.35% of total rea-
gent costs for the centre) – this does not include 
staff (phlebotomist, technician, biochemist and 
portering) and transport costs, and costs of calibra-
tors, controls and maintenance (personal communi-
cation, Dr. C. Evans, Cardiff). In Zagreb, in a 550-bed-
ded teaching hospital, where approximately 16,800 
TSH tests, 11,400 fT3 tests and 14,400 fT4 tests are 
done annually, about 7% of the total annual labora-
tory budget is spent on them (personal communi-
cation, Professor AM Simundic, Zagreb). 
Clinicians have contributed to an increasing labo-
ratory workload by adopting a very low threshold 
for testing, in an attempt at diagnosing subtle thy-
roid dysfunction (10-12). The clinical features of 
thyroid dysfunction are non-specific and often 
mild, e.g. tiredness and lack of energy, and the cli-
nician has to display a high index of suspicion to 
diagnose them. There is also a move towards in-
vestigating and treating subtle thyroid abnormali-
ties in general and particularly in some circum-
stances e.g. pregnancy (13). 
However, clinicians are also responsible for re-
questing thyroid tests inappropriately, particularly 
when individual patient circumstances do not 
warrant such tests (14). For example, some hospi-
tals adopt a policy of a “minimal set” of investiga-
tions in clinical areas admitting acutely ill patients 
(often including thyroid tests). But others don’t, 
and often tests are done at the sole discretion of 
the admitting health care professional, with scant 
regard for patient symptoms or presenting diag-
nosis. In fact it is estimated that of all requests that 
are made to hospital laboratories, about 25 - 40% 
are unnecessary. Within biochemistry the estimate 
of unnecessary tests is even higher at between 
26–98% (15). 
In this regard, the clinical utility of laboratory diag-
nostic pathways needs to be highlighted, particu-
larly in thyroid testing (16). These pathways are 
helpful in differentiating between the causes of 
frequently presenting clinical syndromes and in in-
vestigating rare or complex syndromes, which cli-
nicians do not see often. They are evidence based, 
comply with regulations and are suited to local 
conditions. They will also have the potential to in-
form the clinician of conflicting or potentially con-
fusing pre-analytical circumstances, when used 
within hospital electronic data systems. These 
pathways therefore would have advised against 
thyroid testing in acutely ill patients in the setting 
of the Acute Medical Admissions Unit – unless spe-
cific indications or criteria were fulfilled.
Such indiscriminate thyroid testing should be dis-
couraged in acutely ill patients for several reasons: 
(a) test results are often discordant and difficult to 
interpret (17) particularly for the generalist or non-
specialist; (b) test results are often ignored and not 
followed up by clinicians ordering them; and (c) 
they therefore do not enhance patient manage-
ment or clinical outcome, but only add to the ex-
penses associated with thyroid testing.
The hypothalamic-pituitary-thyroid 
(HPT) axis 
There is an extremely well controlled and finely 
tuned negative feedback mechanism, the HPT axis 
(Figure 1), which maintains thyroid hormones 
within a very narrow range throughout life (5). The 
individual components of the HPT have now been 
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worked out. The hypothalamus secretes thyrotro-
pin releasing hormone (TRH) which is the main 
stimulus to pituitary TSH secretion. TRH secretion 
is in turn inhibited by fT3 and fT4 and influenced 
positively and negatively by a variety of other sub-
stances depicted (Figure 1), both in physiological 
and disease states (7,8). Pituitary TSH secretion, 
which is pulsatile and is highest late evening and 
early morning, is inhibited also by fT3 and fT4 (18). 
The thyroid secretes its major product the prohor-
mone fT4, stimulated by TSH, which is then con-
verted to the active hormone fT3, by intracellular 
deiodinase enzymes both in peripheral and cen-
tral tissues (pituitary and hypothalamus) (19). The 
active hormone fT3, gains access to cells and their 
nuclear thyroid hormone receptors through the 
mechanism of thyroid hormone transporters such 
as organic anion transporter family member 1C1 
(OATP1C1), monocarboxylate transporter 8 (MCT8) 
and MCT10 (20). The effects of other proteins such 
as cytokines, which affect the HPT axis, are depict-
ed in Figure 1.
Non thyroid illness syndrome (NTIS) - 
thyroid tests are discordant and difficult 
to interpret 
The effects of acute illness (and some chronic ill-
nesses) on thyroid hormones and TSH, has been 
known since the 1970s and is currently referred to 
as the non-thyroidal illness syndrome (NTIS) (21). 
There is an ongoing debate about whether the 
changes of NTIS are physiological (or “adaptive”) 
or pathological (or “maladaptive”) (22). In many in-
stances it is a combination of the two, compound-
ed by the effects of drugs (23,24). There appears to 
be no significant intrinsic thyroid dysfunction de-
spite the occasional severity of thyroid hormone 
abnormalities in NTIS (25). However, the jury is still 
out about intervention, as current studies do not 
indicate a need for thyroid hormone replacement 
therapy (25). 
Many mechanisms have been implicated in NTIS, 
and they may be multiple in any one individual 
(24,26). Amongst the most likely are: (a) abnormal 
TRH and TSH secretion; (b) defective deiodinase 
activity; (c) thyroid hormone binding protein (thy-
roglobulin, albumin and transthyretin) and trans-
porter (e.g. MCT8) defects; and (d) altered nuclear 
thyroid hormone receptor activity. Although the 
exact mechanisms causing these changes are un-
known, cytokines such as IL-1, IL-6, and TNF-α may 
be responsible in some types of NTIS (18). Howev-
er, a discussion of these is outside the scope of this 
review.
The biochemical changes of NTIS may begin with-
in the first 24 hours of illness (27). The most com-
mon abnormality is a reduction of free T3 (and a 
rise in reverse T3 which is metabolically inactive 
but not measured clinically). Patients are often sig-
nificantly ill with a poor prognosis when fT4 also 
becomes reduced. In a minority of acutely ill sub-
jects fT4 and fT3 are elevated (5). TSH is low (in 
about 50% of patients) or within the reference 
range. However, TSH is elevated during recovery in 
most (26). Therefore, the combinations of fT4/T3 
and TSH at any given time are discordant (e.g. both 
may be low or high, with other combinations as 
well), difficult to interpret and confusing particu-
larly for the generalist. 
There are several studies that describe this well 
(Table 1). Adlan et al. found that of the 1593 con-
secutive patients admitted with acute illnesses to 
the medical assessment unit of their hospital, 857 
(53.8%) were offered thyroid tests irrespective of 
Figure 1. The hypothalamic-pituitary-thyroid axis (HPT axis).
TRH is secreted by the hypothalamus, TSH by the pituitary 
gland and T4 and T3 by the thyroid gland. Both intrinsic and ex-
trinsic factors affect the HPT axis.
TRH – thyrotropin releasing hormone; TSH – thyroid stimulating 
hormone; TNF – tumour necrosis factor; IL – Interleukin; Alpha-






















https://doi.org/10.11613/BM.2017.033 Biochemia Medica 2017;27(2):300–7 
  303
Premawardhana LD. Thyroid tests and acute illness
their admitting diagnosis or symptoms (28). Of the 
751 subjects who finally had thyroid tests done, 84 
subjects (11.2%) had abnormal thyroid tests. But 
when those on thyroid replacement therapy and 
drugs affecting thyroid function (27 subjects) were 
eliminated from analysis, only 57 (7.6%) had fT4, 
TSH or both, outside the reference range – fT3 is 
not routinely checked. fT4 was within the refer-
ence range (10.3-24.5 pmol/L) in the majority of 
them (69%), below in 12.8% (probably reflecting 
the severity of their illness) and above the refer-
ence range in 18.2%. TSH was within the reference 
range in 18.2%, elevated in 29.1% (TSH > 4.5 mU/L), 
low in 45.5% (0.01 - 0.2 mU/L) and completely sup-
pressed in 7.3% (< 0.01 mU/L) (Figure 2). When the 
audit was repeated four years later, 255 (21.7%) 
subjects who did not have previous thyroid dis-
ease were offered thyroid tests and 19 patients 
(7.5%) had abnormalities. fT4 and TSH were similar-
ly discordant with no particular pattern to the ab-
normalities. The yield of abnormalities in those 
tested for thyroid dysfunction in both audits was 
low (7.6% and 7.5%), the combinations were often 
discordant and unpredictable, and they were diffi-
cult to interpret e.g. high fT4 concentrations were 
associated with normal TSH and normal fT4 with 
low TSH concentrations (Figure 2). Small et al. from 
Scotland found the “sick euthyroid state” in 11.6% 
of a total of 630 consecutive acute medical admis-
sions, with TSH values in the reference range in all 
of them (29). However, fT4 and fT3 were low in 3.5% 
of the total group. 2.1% were given specific treat-
ment for hypothyroidism or hyperthyroidism as 
thyroid tests were suggestive of intrinsic thyroid 
Reference Thyroid abnormalities Comments
(29) TFTs were abnormal in 20% (N = 635)
TFTs in all acute admissions
NTIS in 11.6%
Intrinsic thyroid disease† in 8.3%
(31) TFTs were abnormal in 74.3% (N = 447)
TFTs in all hospitalized elderly patients
NTIS in 62.2%
Intrinsic thyroid disease in 13.4%
(34) Free T4 or TSH was abnormal in 6% and 7.5%(N = 751 and 255 respectively)
Free T4 and TSH in acutely ill patients in MAU
NTIS – 82%
Intrinsic thyroid disease – 18%
(32) TFTs were abnormal in 14% (N = 185)
TFTs in acute haemorrhagic stroke patients
NTIS in 67%
Intrinsic thyroid disease – 14%
(40) TFTs were abnormal in 31.8% (N = 503)
TFTs in subjects with community acquired pneumonia
NTIS in 31.8%
Patients with known thyroid disease were excluded from analysis
NTIS – non thyroid illness syndrome; †hypothyroidism, hyperthyroidism or their subclinical variants; TFT – thyroid function tests; 
T4 – free thyroxine; TSH - thyroid stimulating hormone; MAU - medical admissions unit.
Table 1. Thyroid testing in subjects with acute illness
Figure 2. Pattern of thyroid abnormalities in acutely ill patients.
Free thyroxine (fT4) and TSH tests were discordant in many with 
abnormal thyroid tests and the combinations were difficult 
to interpret e.g. normal TSH combined with high fT4; low TSH 
combined normal fT4 etc. – adapted from (34). 
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disease. In a similar study from Italy the authors 
found a relatively high number of inappropriate 
thyroid test requests (22.4% of 464 requests) from 
the emergency department of their hospital, 
which were difficult to interpret and had little clini-
cal utility (14). The yield of thyroid test abnormali-
ties in acutely ill subjects is relatively low as the 
above studies indicate (between 7.4 and 20%).
NTIS occurs in non-critically ill patients 
The majority of hospital patients have non-critical 
illnesses. Although NTIS was initially described in 
critically ill patients in Intensive Therapy units (ITU), 
there is accumulating evidence that NTIS also oc-
curs in subjects who are acutely but not critically ill 
i.e. not requiring ITU treatment (Table 2) (30-33). 
These studies have demonstrated a high incidence 
of NTIS (up to 62% in some) in subjects with acute 
but non-critical illness – cardiac, stroke and other 
illnesses such as pneumonia. Therefore, physicians 
should be aware of this phenomenon when thy-
roid tests are requested in areas where acutely ill 
patients are admitted even if they are not “critical-
ly” ill.
The clinical utility of thyroid tests in the 
acutely ill patient
The clinical utility of thyroid tests in acute illness 
remains doubtful. Clinical experience indicates 
that in addition to the poor yield of abnormalities 
and discordant and difficult to interpret thyroid 
hormone and TSH combinations, physicians do 
not intervene or follow these patients after their 
acute admission. In other words, these tests are 
not of high clinical utility.
Abnormal thyroid results are ignored
In the study by Adlan et al., 25.5% of patients with 
abnormal thyroid tests, the majority of whom 
were known to have previous thyroid disease, had 
either thyroid related medication introduced or 
dose adjusted (34). However, 74.5% of those with 
thyroid abnormalities had no documented inter-
vention following the detection of thyroid abnor-
malities. As most of these patients were admitted 
under the care of “non-Endocrine specialist” physi-
cians (specialists in Care of the Elderly Medicine, 
Gastroenterology etc.), it appeared that they did 
not have the expertise nor the inclination to deal 
with them and as a result there was no interven-
tion planned – intervention defined here as 
planned follow up after the acute illness, or inves-
tigation and treatment while in hospital. It is clear 
that the majority of patients with abnormal thy-
roid results are not followed up.
Inadequate follow up and intervention
In the same study by Adlan et al., only 45.5% of 
subjects with abnormal thyroid results were fol-
lowed up after the index admission (median 8 
weeks; range 1-39 weeks) (34). Thyroid tests had 
become normal in 9 of these (36%), but remained 
abnormal in 6 patients who were known to have 
previous thyroid disease and 10 who were not 
(64%). No further action was planned for these 
(34). It is clear from the above that thyroid testing 
in this group of individuals did not influence clini-
cal outcome.
Study (reference) Remarks
Acute MI (non critical);
N = 331
(30)
Reverse T3 associated 
with mortality
Various non critical cardiac illness;
N = 573
(32)
Free T3 associated with 
survival









Low free T3 associated 
with short term and 
long term outcome
MI – Myocardial Infarction; NTIS – Non thyroidal illness 
syndrome.
Table 2. Studies in non-critically ill subjects who showed bio-
chemical features of NTIS
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How do we reduce thyroid testing in 
acutely ill patients?
Inappropriate thyroid testing in the presence of 
acute illness has multiple significant consequenc-
es – unnecessary expense, increasing laboratory 
workload, waste of scarce resources and potential 
negative impact on patient health (often involving 
further testing and inappropriate treatment) (13). 
One effective way of reducing these consequenc-
es is to reduce the number of test requests by 
changing requestor behavior. 
There are many interventions that may be em-
ployed to change requestor behaviour. Two re-
views summarise them as follows: (a) educational 
interventions; (b) guideline and protocol develop-
ment; (c) changes to funding arrangements; (d) 
use of existing guidelines and protocols; (e) deci-
sion making tools – request forms and computer 
based decision support; (f) audit and feedback (35-
37). Where requestor behaviour needs to be modi-
fied, the type of intervention that is relevant to lo-
cal circumstances needs to be utilised. 
Successful interventions to reduce thyroid testing 
in acutely ill subjects involving requestor educa-
tion and audit, adopted in two hospitals in South 
East Wales, will now be described.
Educational intervention
In a 500 bedded district general hospital in Wales, 
950 acutely ill patients were admitted on average 
per month to the medical admissions unit (MAU) – 
this did not include patients with suspected poi-
soning who were admitted to a specialist ward. 
Each month 309 thyroid function tests, 481 lipid 
profiles and 818 coagulation screens were request-
ed for these patients on average. These requests 
were made primarily at the time of triage by nurs-
ing staff. Following the identification that these 
test requests were excessive, discussions were 
held between the Laboratory staff and the clini-
cians in the MAU. They removed these three sets 
of investigations from the standard MAU biochem-
istry test request forms and agreed a new protocol 
for biochemical testing. They also implemented an 
educational intervention in the MAU as follows: (a) 
lectures and tutorials delivered to all clinical staff; 
(b) posters describing new protocol for laboratory 
requests were displayed in prominent areas in the 
MAU; (c) protocol and data presented to the Medi-
cal Directorate Governance and Safety committee 
for review. When pre-intervention request behav-
iour was compared to post-intervention request 
behaviour calendar month to calendar month (to 
rule out seasonal variation), a significant reduction 
was observed in thyroid tests requested per pa-
tient (0.32 before intervention (SD 0.05) vs. 0.08 
post intervention (SD 0.01); P < 0.001) (38). This was 
also true for the other tests removed from the 
standard request protocol. The authors of this 
study concluded that in addition to cost savings, 
this study improved the appropriateness of testing 
and improved patient care (38).
Thyroid testing guidelines and audit
In the study discussed above, following an initial 
audit, the authors issued guidelines about thyroid 
testing in acute illness, and repeated the audit 4 
years later (34). Whereas thyroid tests were offered 
to 53.8% acutely ill subjects in the first audit, this 
was reduced to 21.7% in the second (P = 0.01). Fur-
thermore as mentioned above, physicians acted 
upon reviewing the results and follow up was ar-
ranged for a significantly higher percentage of 
subjects following the second audit (Table 3).
Audit 1 Audit 2
Number of admissions studied 1593 1176
Number of offered TFT, N (%) 857 (53.8) 255 (21.7)*
Prevalence of thyroid 
abnormalities (%)
7.6 7.5
Action taken (%) 25.5 92.7*
Follow up (%) 45.5 85.7*
*There was a significant decrease in the number of thyroid 
tests offered, and an increase in the proportion of patients 
on whom action was taken and follow up arranged, after 
implementing guidelines for thyroid testing in acutely ill 
subjects (34).
TFT – thyroid function tests.
Table 3. Comparison of thyroid testing in acutely ill subjects - 
after implementing thyroid testing guidelines.
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Conclusions
Measuring thyroid hormones and TSH in acutely ill 
patients is often an expensive distraction and is 
only of limited clinical value. The yield of abnormal 
thyroid tests is low, the tests are discordant and of-
ten difficult to interpret for the generalist (as they 
do not fit recognizable patterns), and are often ig-
nored by the requesting physician (34). In addition 
to being a distraction clinically, they are also ex-
pensive to do and in some hospitals account for a 
significant proportion of the laboratory services 
budget. Education of nurses, junior doctors and 
senior physicians in the futility of thyroid testing 
during acute illness, helps in reducing the number 
of tests done, as has been shown in two recent 
studies (34,38). Efforts should be made to devise a 
sensible, logical and easily understood set of 
guidelines for targeted thyroid testing in acutely ill 
patients in hospital medical assessment units (39). 
The following criteria for targeted thyroid testing 
were adopted in our medical assessment unit with 
improved results i.e. with a significant reduction in 
thyroid test requests, a higher proportion of re-
sults being acted upon, and more patients being 
followed up after the acute illness:
•	 patients with symptoms or signs of thyroid dis-
ease e.g. goiter, orbitopathy 
•	 patients with risk factors for thyroid disease, 
previous or family history of thyroid disease
•	 patients taking drugs which potentially affect 
thyroid function e.g. thyroxine replacement 
therapy, amiodarone, lithium, mechanistic tar-
get of rapamycin (mTOR) inhibitors, interferon, 
alemtuzumab etc.
•	 unexplained tachydysrhythmias.
Changing requestor behaviour in reducing inap-
propriate thyroid testing in acutely ill patients is a 
worthwhile exercise, and emerging evidence indi-
cates audit and education of healthcare profes-
sionals are interventions that should be explored.
Potential conflict of interest
None declared.
References
 1. Fliers E, Kalsbeek A, Boelen A. Beyond the fixed setpoint of 
the hypothalamo-pituitary-thyroid axis. Eur J Endocrinol 
2014;171:197-208. https://doi.org/10.1530/EJE-14-0285
 2. Andersen S, Pedersen KM, Bruun NH. Narrow individual va-
riations in serum T(4) and T(3) in normal subjects: a clue to 
the understanding of subclinical thyroid disease. J Clin En-
docrinol Metab 2002;87:1068–72. https://doi.org/10.1210/
jcem.87.3.8165 
 3. Duntas LH. New insights into the hypothalamic-pituitary-
thyroid axis. Acta Endocrinol 2016;12:125-129. https://doi.
org/10.4183/aeb.2016.125
 4. Bahn RS. Autoimmunity and Graves’ disease. Clin Phar-
macol Ther 2012;91:577-579. https://doi.org/10.1038/
clpt.2012.10
 5. Ortiga-Carvalho TM, Chiamolera MI, Pazos-Moura CC, 
Wondisford FE. Hypothalamus-Pituitary-Thyroid Axis. Com-
prhen Physiol 2016;6:1387–1428. https://doi.org/10.1002/
cphy.c150027
 6. Ajjan RA, Weetman AP. The Pathogenesis of Hashimoto’s 
Thyroiditis: Further Developments in our Understan-
ding. Horm Metab Res 2015;4:702-710. https://doi.
org/10.1055/s-0035-1548832
 7. Plebani M. Errors in Clinical laboratories or errors in labo-
ratory medicine? Clin Chem Lab Med 2006;44;750-759. 
https://doi.org/10.1515/CCLM.2006.123
 8. Beckett GJ, Toft AD. First line thyroid function tests – TSH 
alone is not enough. Clin Endocrinol (Oxf) 2003;58:20-21. 
https://doi.org/10.1046/j.1365-2265.2003.01690.x
 9. Association for Clinical Biochemistry, British Thyroid Asso-
ciation, British Thyroid Foundation. UK Guidelines for the 
use of thyroid function tests. Available at: http://www.btf-
thyroid.org/images/stories/pdf/tft_guideline_final_versi-
on_july_2006.pdf. Accessed June 16th 2016.
10. Bayram C, Valenti L, Britt H. Orders for thyroid functi-
on tests— changes over 10 years. Aust Fam Physician 
2012;41:555-9. 
11. Leese GP, Flynn RV, Jung RT, Macdonald TM, Murphy MJ, 
Morris AD. Increasing prevalence and Incidence of thyro-
id disease in Tayside, Scotland: the Thyroid Epidemiology 
Audit and Research Study (TEARS). Clin Endocrinol (Oxf) 
2008;68:311–6.
12. Newchurch Ltd., National Pathology Benchmarking Report 
2000/2001. London: Newchurch 2002.
https://doi.org/10.11613/BM.2017.033 Biochemia Medica 2017;27(2):300–7 
  307
Premawardhana LD. Thyroid tests and acute illness
13. Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, Gre-
enwood R, et al. Falling Threshold for Treatment of Borderli-
ne Elevated Thyrotropin Levels—Balancing Benefits and Ri-
sks: Evidence From a Large Community-Based Study. JAMA 
Intern Med 2014;174:32-39. https://doi.org/10.1001/jama-
internmed.2013.11312
14. Giacomini A, Chiesa M, Carraro P. Urgent thyroid stimula-
ting hormone testing in emergency medicine: a useful tool? 
J Emerg Med 2015;49:481-487. https://doi.org/10.1016/j.je-
mermed.2015.05.003
15. Gopal Rao G, Crook M, Tillyer MI. Pathology tests: is the 
time for demand management ripe at last? J Clin Pathol 
2003;56:243-8. https://doi.org/10.1136/jcp.56.4.243
16. Hoffmann G, Aufenanger J, Födinger M, Cadamuro J, von 
Eckardstein A, Kaeslin-Meyer M, Hofmann M. Benefits and 
limitations of laboratory diagnostic pathways. Diagnosis 
2014;1:269-27. https://doi.org/10.1515/dx-2014-0045
17. Koulouri O, Moran C, Halsall D, Chatterjee K, Gur-
nell M. Pitfalls in the measurement and interpretati-
on of thyroid function tests. Best Pract Res Clin Endocri-
nol Metab 2013;30:745–762. https://doi.org/10.1016/j.
beem.2013.10.003
18. Fliers E, Kalsbeek A, Boelen A. Mechanisms in endocrino-
logy: Beyond the fixed set point of the hypothalamus–pi-
tuitary–thyroid axis. Eur J Endocrinol 2014;171:R197–207. 
https://doi.org/10.1530/EJE-14-0285
19. Bianco AC, Kim BW. Deiodinases; implications of the 
local control of thyroid hormone action. J Clin Invest 
2006;116:2571-9. https://doi.org/10.1172/JCI29812 
20. Visser WE, Friesma EC, Visser TJ. Minireview; thyroid hormo-
ne transporters: the knowns and unknowns. Mol Endocrinol 
2011;25:1-14. https://doi.org/10.1210/me.2010-0095
21. de Vries EM, Fliers E, Boelen. The molecular basis of the non-
thyroidal illness syndrome. J Endocrinol. 2015;225:R67-81. 
https://doi.org/10.1530/JOE-15-0133
22. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid func-
tion in critically ill patients. Lancet Diabetes Endocri-
nol 2015;3:816-25. https://doi.org/10.1016/S2213-
8587(15)00225-9.
23. Haugen BR. Drugs that suppress TSH or cause cen-
tral hypothyroidism. Best Pract Res Clin Endocri-
nol Metab 2009;23:793–800. https://doi.org/10.1016/j.
beem.2009.08.003
24. van den Berghe G. Non-Thyroidal Illness in the ICU: A Syn-
drome with Different Faces. Thyroid 2014;24:1456–65. 
https://doi.org/10.1089/thy.2014.0201
25. Pappa TA, Vagenakis AG, Alevizaki M. The nonthyroidal ill-
ness syndrome in the non-critically ill patient. Eur J Clin 
Invest 2011;41:212-20. https://doi.org/10.1111/j.1365-
2362.2010.02395.x
26. Warner MH, Beckett GJ. Mechanisms behind the non-thyro-
idal illness syndrome; an update. J Endocrinol 2010;205:1-
13. https://doi.org/10.1677/JOE-09-0412
27. Wajner SM, Maia AL. New insights toward the acute non-
thyroidal illness syndrome. Front Endocrinol 2012;3:1-7. 
https://doi.org/10.3389/fendo.2012.00008
28. Adlan MA, Neel V, Lakra SS, Bondugulapati LNR, Pre-
mawardhana LD. Targeted thyroid testing in acute illne-
ss: Achieving success through audit. J Endocrinol Invest 
2011;34:e210-3.
29. Small M, Buchanan L, Evans R. Value of screening thyro-
id function in acute medical admissions to hospi-
tal. Clin Endocrinol (Oxf) 1990;32:185–91. https://doi.
org/10.1111/j.1365-2265.1990.tb00854.x
30. Iervasi G, Pinitore A, Landi P, Raciti M, Ripoli A et al. Low T3 
syndrome; a strong prognostic predictor of death in pa-
tients with heart disease. Circulation 2003;107:708-13. 
https://doi.org/10.1161/01.CIR.0000048124.64204.3F
31. Iglesias P, Munoz A, Prado F, Guerrero MT, Macias MC et al. 
Alterations in thyroid function tests in aged hospitalized 
patients; prevalence, aetiology and clinical outcome. Clin 
Endocrinol (Oxf) 2009;70:961-7. https://doi.org/10.1111/
j.1365-2265.2008.03421.x
32. Pande A, Goel VK, Rastogi A, Gupta A. Thyroid dysfuncti-
on in patients with haemorrhagic stroke. Thyr Res Pract 
2016;13:19-24. https://doi.org/10.4103/0973-0354.159531
33. Alevizaki M, Synetou M, Xynos K, Pappa T, Vemmos KN. Low 
triiodothyronine; a strong predictor of outcome in acute 
stroke patients. Eur J Clin Invest 2007;37:651-7. https://doi.
org/10.1111/j.1365-2362.2007.01839.x
34. Adlan MA, Neel V, Lakra SS, Bondugulapati LNR, Premawar-
dhana LD. Targeted thyroid testing in acute illness: Achie-
ving success through audit. J Endocrinol Invest 2011;34:210-
213.
35. Solomon DH, Hashimoto H, Daltroy D et al. Techniques to 
improve clinicians’ use of diagnostic tests; a conceptual fra-
mework. JAMA 1998;280:2020-24. https://doi.org/10.1001/
jama.280.23.2020 
36. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic 
bullet; a systematic review of 102 interventions to improve 
professional practice. CMAJ 1995;153:1423-31.
37. Zhelev Z, Abbott R, Rogers M, Fleming S, Patterson A, Ha-
milton WT et al. Effectiveness of interventions to redu-
ce ordering of thyroid function tests: a systematic review. 
BMJ Open 2016;6:e01006. https://doi.org/10.1136/bmjo-
pen-2015-010065
38. Willis E, Datta DN. Effect of an educational interventi-
on on requesting behavior by a medical admission unit. 
Ann Clin Biochem 2013;50:166-8. https://doi.org/10.1258/
acb.2012.012100
39. Bellew SD, Moman R, Lohse CM, Hess EP, Bellolio MF. Valida-
tion of a decision rule for selective TSH screening in atrial fi-
brillation. West J Emerg Med 2015;16:195-202. https://doi.
org/10.5811/westjem.2014.11.23490
40. Liu J, Wu X, Lu F, Zhao L, Shi L, Xu F. Low T3 syndrome is a 
strong predictor of poor outcome in patients with commu-
nity acquired pneumonia. Sci Rep 2016;6:22271. https://doi.
org/10.1038/srep22271
